Can Your Gut Health Affect Your Brain? What Sialylated HMOs Reveal About the Gut-Brain Axis

You've probably heard that a troubled gut can mean a troubled mind. Stress triggers stomach pain. Anxiety causes nausea. Poor sleep wrecks digestion. But most people assume this is a one-way street — that the brain is driving the gut, not the other way around.

The science tells a very different story. The gut actively signals to the brain. It produces neurotransmitters, regulates inflammation, shapes how we think, feel, and focus — and when that relationship breaks down, cognitive function is one of the first things to suffer.

What's even more remarkable — and almost entirely overlooked by the supplement industry — is the specific role of sialylated human milk oligosaccharides (HMOs) in this relationship. These aren't just prebiotic fibers. They're structural contributors to the brain itself.

What Is the Gut-Brain Axis, and Why Does It Matter?

The gut-brain axis is the bidirectional communication network linking the gastrointestinal tract and the central nervous system. It operates through several overlapping channels:

• The vagus nerve — a direct neural highway carrying signals from the gut microbiome up to the brainstem.
• The enteric nervous system — often called the "second brain," housing over 500 million neurons in the gut wall.
• Immune signaling — gut inflammation generates cytokines that cross into systemic circulation and reach the brain.
• Short-chain fatty acids (SCFAs) — microbial metabolites like butyrate that cross the blood-brain barrier and influence neuronal function.
• Neurotransmitter precursors — approximately 90% of the body's serotonin is synthesized in the gut.

A 2024 narrative review published in Nutrients (Falsaperla et al., PMID 39275324) documented how HMOs modulate every one of these pathways — shaping the microbiota, reducing inflammation, and influencing neurotransmitter production to support what the authors call a "neuroprotective gut environment."

But there's one pathway that most HMO science has barely touched — and it may be the most important of all.

What Is Sialic Acid — and Why Is It Critical for Your Brain?

Sialic acid is a sugar-like molecule found on the outer surface of nearly every cell in your body. In the brain, it plays an outsized role.

Brain gangliosides — lipid molecules embedded in neural membranes — are heavily sialylated. They include GM1, GM2, GM3, GD1a, GD1b, and GQ1b. These gangliosides are not decorative. They govern:

• Neural membrane integrity and stability
• Synaptic transmission and plasticity
• Neuronal differentiation and repair
• Long-term potentiation (the cellular basis of memory)

A landmark review published in Annual Review of Nutrition (Wang B., PMID 19575597) established that sialic acid is an essential nutrient for brain development and cognition — the first comprehensive case for sialic acid as a true cognitive nutrient, not just a structural molecule.

A 2022 review (PMID 35531941) reinforced this: sialic acid deficiency correlates with impaired ganglioside synthesis, and reduced ganglioside density has been associated with pathologies including Alzheimer's disease. The authors concluded that maintaining adequate sialic acid bioavailability across the lifespan — not just in infancy — may matter significantly for cognitive maintenance.

Where Do Sialylated HMOs Fit In?

Here's where it gets fascinating. Breast milk is the richest known dietary source of sialylated oligosaccharides. The body doesn't synthesize sialic acid in large quantities on its own — it depends heavily on dietary intake, particularly from sialylated structures that can be metabolized and redirected to the brain.

The pathway works like this:

1. Sialylated HMOs (including 3'-sialyllactose and 6'-sialyllactose) survive digestion and reach the colon intact.
2. The gut microbiome processes them, releasing free sialic acid and producing SCFAs as metabolic byproducts.
3. Free sialic acid enters systemic circulation and is incorporated into ganglioside biosynthesis in neural tissue.
4. SCFAs cross the blood-brain barrier and support neuronal energy metabolism and synaptic function.

A 2018 study in Nutrients (Oliveros et al., PMID 30332832) demonstrated this pathway directly: rats supplemented with sialic acid and sialylated oligosaccharides during lactation showed significant improvements in learning and memory compared to controls — measurable improvements tied directly to sialic acid bioavailability.

And critically, the effect appears to extend beyond infancy. Adults don't stop needing sialic acid. The gangliosides in adult neural tissue undergo continuous turnover. The question is whether modern diets — stripped of breast milk and low in sialylated structures — are keeping up with demand.

What the Research Shows About Sialylated HMOs and Cognitive Outcomes

The landmark study here is a 2021 paper from Molecular Psychiatry (Pisa et al., PMID 33664475). Researchers used a mouse model in which offspring were deprived of 6'-sialyllactose (6'SL) — one of the primary sialylated HMOs in breast milk — during the lactation period.

The results were striking. Mice deprived of 6'SL showed:

• Impaired object recognition memory
• Reduced spatial reference memory in Barnes maze testing
• Diminished attentional capabilities
• Disrupted hippocampal long-term potentiation (LTP) — the electrophysiological signature of memory encoding
• Altered serotonergic metabolism via downstream gut microbiota changes

These impairments persisted into adulthood — well beyond the lactation period in which 6'SL was withheld. The researchers traced the mechanism to reduced expression of genes involved in prefrontal cortex development at a critical window of neural patterning.

Separate research (Tarr et al., PMID 26144888) found that supplementation with 3'-sialyllactose (3'SL) and 6'SL reduced stressor-induced anxiety-like behavior and colonic microbiota disruption in mice — direct evidence that sialylated HMOs modulate the gut-brain axis in real time, not just during development.

In human infant data, a 2021 clinical study (Cho et al., PMID 34020453) found that exposure to 3'-sialyllactose in breast milk was positively associated with language development by 10 months of age — with stronger effects in expressive and receptive language in infants over 12 months. Language acquisition is a direct readout of neural circuit maturation.

The Problem With Single-Strain HMO Supplements

The HMO supplement market has grown rapidly — but most products focus exclusively on non-sialylated HMOs. The most commonly sold ingredient, 2'-fucosyllactose (2'-FL), is a fucosylated HMO. It has real prebiotic benefits. But it contains zero sialylated fraction.

This means a supplement built around a single non-sialylated HMO will entirely miss the sialic acid pathway. No sialylated HMOs means no dietary sialic acid contribution — and no support for the ganglioside synthesis that underlies long-term cognitive health.

This is exactly the gap that kpHMO™ was designed to fill.

kpHMO™ — a proprietary ingredient designed and owned exclusively by kēpos — is the only supplement ingredient formulated to cover all neutral, fucosylated, AND sialylated HMO bases, including the sialylated fractions directly linked to gut-brain axis signaling.

It mirrors the oligosaccharide complexity of real breast milk — including the sialylated HMOs that competitors' single-strain products simply don't contain. That's not a minor distinction. When it comes to the gut-brain axis, the sialylated fraction may be doing the heaviest neurological lifting of all.

What About effera™ Human Lactoferrin?

kēpos doesn't stop at HMOs. Every serving also includes effera™ recombinant human lactoferrin (rhLF) — and the neurological implications of lactoferrin are increasingly compelling.

A 2023 review (PMID 37731953) confirmed that lactoferrin undergoes receptor-mediated transcytosis across the blood-brain barrier — meaning it can physically cross from the bloodstream into the brain. Lactoferrin receptors exist on brain capillary endothelial cells, and once inside, lactoferrin may support:

• Microglial function — the brain's immune cells, which when dysregulated drive neuroinflammation
• Neuro-redox regulation — protecting neurons from oxidative stress
• Anti-inflammatory signaling — reducing the systemic inflammatory burden that translates into neuroinflammation

The gut-inflammation-to-neuroinflammation pipeline is well documented: increased intestinal permeability allows lipopolysaccharide (LPS) — a bacterial endotoxin — to translocate into systemic circulation. Circulating LPS activates microglia, the brain's immune cells, driving neuroinflammation that impairs cognition, mood, and focus.

HMOs support gut barrier integrity by promoting tight junction proteins, directly reducing LPS translocation. Lactoferrin's own antimicrobial and anti-inflammatory properties reinforce that barrier defense. Together, kpHMO™ and effera™ address the gut-brain inflammatory axis from both ends.

What This Means for Brain Fog, Focus, and Mental Performance

Brain fog, low motivation, difficulty concentrating — these experiences are common, and most people reach for caffeine or nootropics. But for many individuals, the gut is the missing piece.

Gut dysbiosis reduces SCFA production. Increased gut permeability elevates systemic LPS. Disrupted serotonin synthesis (90% of which originates in the gut) alters mood and cognition. Low sialic acid bioavailability impairs the ongoing maintenance of neural gangliosides.

None of these pathways will respond to caffeine. They respond to targeted gut support.

kēpos, featuring kpHMO™ and effera™ human lactoferrin, is designed to address each of these mechanisms — prebiotic modulation of the microbiome, sialylated HMOs to support the sialic acid pathway, improved gut barrier integrity to reduce neuroinflammatory burden, and lactoferrin's direct neurological activity.

Explore kēpos and discover what the full spectrum of human milk bioactives can do for your gut — and your brain.

---

Frequently Asked Questions

Written by Oliver Drazsky. For educational purposes only. These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease.

Cited studies: PMID 33664475 | PMID 39275324 | PMID 26144888 | PMID 30332832 | PMID 34020453 | PMID 35531941 | PMID 19575597 | PMID 37731953